Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

Published:2006-01-01 Issue:1 Volume:12 Page:242-249
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

DiJoseph John F.,Dougher Maureen M.,Kalyandrug Lyka B.,Armellino Douglas C.,Boghaert Erwin R.,Hamann Philip R.,Moran Justin K.,Damle Nitin K.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11

2. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial;American Journal of Hematology;2024-02-23

3. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences;Exploration of Targeted Anti-tumor Therapy;2022-12-26

4. In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies;Cancers;2022-03-01

5. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate;Pharmaceutics;2022-02-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP